IMMODULON THERAPEUTICS LTD.
Immodulon is a privately-owned immuno-oncology company primarily focused on the development of novel, safe, effective and potentially valuable treatments for cancer. Their IMM-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. They are currently developing treatments for advanced melanoma, a skin cancer, and for advanced pancreatic cancer.
IMMODULON THERAPEUTICS LTD.
Social Links:
Industry:
Biotechnology Therapeutics
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.immodulon.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0) 20 3137 6346
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics
Similar Organizations
GlyTherix Ltd.
GlyTherix Ltd. is an Australian immuno-oncology company
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Current Employees Featured
Founder
Official Site Inspections
http://www.immodulon.com
- Host name: a67c48129651a0940.awsglobalaccelerator.com
- IP address: 13.248.213.45
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Immodulon Therapeutics Ltd."
Immodulon Therapeutics Ltd. - Crunchbase Company …
Immodulon is a privately-owned immuno-oncology company primarily focused on the development of novel, safe, effective and potentially valuable treatments …See details»
Immodulon Therapeutics Ltd
Immodulon is a late-stage clinical biotechnology company developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a …See details»
About Immodulon Immunotherapy Treatments
Immodulon is a late-stage clinical biotechnology company developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the …See details»
Immodulon
T: +44 (0) 20 3137 6346 | E: [email protected] Company Address: 6-9 The Square, Stockley Park, Uxbridge UB11 1FW Registered Address: 6-9 The Square, Stockley Park, Uxbridge …See details»
Immodulon Company Profile 2024: Valuation, Funding & Investors …
Immodulon General Information Description. Developer of novel drugs designed to provide treatment to cancer patients. The company's drug offers immunotherapy, chemotherapy, radio …See details»
Immodulon Therapeutics Company Profile | Management and
Immodulon Therapeutics Ltd. (London, UK) is a privately-owned, clinical-stage, immuno-oncology company primarily focused on the development of safe, effective and novel treatments for …See details»
IMMODULON THERAPEUTICS LIMITED - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for IMMODULON THERAPEUTICS LIMITED of UXBRIDGE. Get the latest business insights from Dun & …See details»
Immodulon Therapeutics Limited Information - RocketReach
IMMODULON, LEADERS IN IMMUNO-ONCOLOGY Immodulon Therapeutics Ltd. is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of …See details»
Immodulon Therapeutics - Overview, News & Similar companies
Jun 5, 2023 Immodulon Therapeutics Ltd. (London, UK) is a privately-owned, clinical-stage, immuno-oncology company primarily focused on the development of safe, effective and novel …See details»
Immodulon Therapeutics Ltd. - Drug pipelines, Patents, Clinical …
Explore Immodulon Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 9 news, and 9 literature, Disease Domain ...See details»
Immodulon Therapeutics - VentureRadar
Immodulon is a privately-owned immuno-oncology company primarily focused on the development of novel, safe, effective and potentially valuable treatments for cancer. Our IMM …See details»
Immodulon Therapeutics Limited (In Administration) - Hilco …
Immodulon Therapeutics Limited is a late-stage clinical biotechnology company founded in 2007 and based in the United Kingdom. The Company is researching a highly differentiated cancer …See details»
Immodulon Aims to Activate Both Arms of Immune System To …
Aug 26, 2024 Response: Immodulon’s flagship treatment, IMM-101 is a naturally-occurring, non-pathogenic (incapable of causing disease), heat-killed whole cell mycobacterium called M. …See details»
Immodulon Therapeutics Ltd - BIO CEO & Investor Conference | BIO
Feb 6, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Immodulon …See details»
Immodulon Therapeutics Ltd. - Contacts, Employees, Board …
Organization. Immodulon Therapeutics Ltd. Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. …See details»
Immodulon to Participate in the Wells Fargo Virtual Private Biotech ...
Apr 29, 2024 Immodulon is a late-stage clinical biotechnology company developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune …See details»
Immodulon, Champalimaud Foundation team up on ‘difficult to …
Aug 3, 2020 London, UK-based Immodulon has teamed up with Lisbon, Portugal-based non-profit organisation the Champalimaud Foundation to research and examine the potential use …See details»
IMM-101, an immunotherapeutic agent in clinical development as …
IMM-101 is an immunotherapeutic agent in clinical development as an adjunctive treatment in cancer. It comprises heat-killed whole cell Mycobacterium obuense and is being developed by …See details»
Immodulon announces that IMM-101 will be evaluated in world …
Jul 9, 2020 Funding and in-kind support, valued at $2.8 million, is being provided by the Canadian Cancer Society, BioCanRx, the Ontario Institute for Cancer Research, The Ottawa …See details»
Immodulon Therapeutics Limited - Caseboard
Dec 12, 2024 Immodulon Therapeutics Limited Dec. 12, 2024. Case Information. Case Number CR-2024-007586. Court/List. Companies Application - Notice of Intention to appoint an …See details»